About us

NAL Pharma

NAL Pharma applies its proprietary Drug Delivery System (“DDS”) technologies to develop novel drug dosage forms and delivery systems, including:

• Bio-D3 Transdermal Patch DDS Technology 
• Bio-FX Fast-Onset Orally-Dissolving Film (ODF) DDS Technology
• Bio-CR Oral Controlled-Release Injectable DDS Technology
• Bio-NN Nanoparticle Controlled-Release Injectable DDS Technology
• Bio-MM Microsphere Extended-Release "Depot" Injectable DDS Technology

NAL utilizes its captive proprietary DDS technologies to:

• Convert patent-expiring blockbuster drugs into new DDS with improved features
• Develop products with enhanced patient compliance, safety, efficacy, and/or user convenience
• Improve quality attributes of products, such as stability, solubility, and delivery efficiency
• Extend product life cycles with new patent protections

By working with major pharmaceutical companies, NAL also utilizes its proprietary DDS technologies to:

• Advance the drug delivery systems of their new drug entities under development, in an effort to develop the best possible delivery systems at the earliest development stage
• Develop the new generation of their approved products by improving existing formulation

NAL is a privately owned corporation, headquartered in Hong Kong, working with international pharmaceutical development laboratories and manufacturing operations in the Asia, and Europe, in an effort to expedite the product development and commercialization of NAL’s products with international marketing partners in global markets.